Eli Lilly Begins Phase 3 Trial of Olumiant for COVID-19 Patients

Eli Lilly has begun enrolling patients for a phase 3 trial of its rheumatoid arthritis treatment Olumiant (baricitinib) for hospitalized COVID-19 patients.

The trial will examine the proportion of patients treated with 4 mg of Olumiant who die or require ventilation by day 28 compared with those given a placebo.

Lilly said the study will complement other ongoing baricitinib trials in COVID-19 patients, included one being conducted by the National Institute of Allergy and Infectious Diseases.